U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.